BioLoomics
BioLoomics is a biotechnology company focused on developing safer and more effective cancer therapies by engineering Antibody Drug Conjugates (ADCs). They utilize a directed evolution approach, combining advanced bioinformatics, AI, and high-throughput wet-lab testing to create 'Super-ADCs'. These Super-ADCs incorporate membrane-binding peptides to enhance payload delivery, improve internalization, and increase target-specific cytotoxicity. The company aims to overcome the limitations of traditional ADCs, targeting clinically validated oncology targets. BioLoomics has secured $8.7 million in seed funding and appointed Kurt Gish as Chief Scientific Officer to advance their pipeline.
BioLoomics
BioLoomics is a biotechnology company focused on developing safer and more effective cancer therapies by engineering Antibody Drug Conjugates (ADCs). They utilize a directed evolution approach, combining advanced bioinformatics, AI, and high-throughput wet-lab testing to create 'Super-ADCs'. These Super-ADCs incorporate membrane-binding peptides to enhance payload delivery, improve internalization, and increase target-specific cytotoxicity. The company aims to overcome the limitations of traditional ADCs, targeting clinically validated oncology targets. BioLoomics has secured $8.7 million in seed funding and appointed Kurt Gish as Chief Scientific Officer to advance their pipeline.